PTK2 and hepatocellular carcinoma: We selected Defactinib (FAK inhibitor) and Saracatinib (Src inhibitor) to evaluate their efficacy on HCC cells, because several clinical trials of these two inhibitors for cancer treatment are underway (https://clinicaltrials.gov).